TY - JOUR
TI - Antiplatelet and Antithrombotic Therapy in Type I Diabetes Mellitus: Update on Current Data.
AU - Maragkoudakis, Spyridon
AU - Katsi, Vasiliki
AU - Melidonis, Andreas
AU - Soulaidopoulos, Stergios
AU - Kolovou, Genovefa D.
AU - Papazafeiropoulou, Athanasia K.
AU - Trikkalinou, Aikaterini
AU - Toutouzas, Konstantinos
AU - Tsioufis, Constantinos
JO - Current Diabetes Reviews
PY - 2022
VL - null
TODO - null
SP - null
PB - 
SN - 1573-3998
TODO - 10.2174/1573399818666220103091236
TODO - cardiovascular disease, venous thromboembolism, antiplatelet therapy, antithrombotic therapy, LDL, Type1 diabetes mellitus
TODO - Diabetes mellitus type 1 (T1DM) is an autoimmune disease characterized by a markedly elevated cardiovascular (CV) risk due to premature atherosclerosis. Previous studies  have shown that intense glycemic control reduces the incidence of CV disease.  Antiplatelet therapy is considered to be a very important therapy for secondary  prevention of recurrent atherothrombotic events in patients with DM, while it may be  considered for primary prevention in individuals with T1DM with additional CV risk  factors.The aim of the present review is to summarize existing literature data  regarding the thrombotic risk in T1DM patients and discuss current treatment  strategies.
ER -